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Abstract — Aims: This review assessed the published data on the cost-effectiveness of acamprosate for the treatment of alcohol
dependence. Methods: Four Markov modelling studies have assessed the therapeutic benefit and economic impact of acamprosate on
the treatment of alcohol dependence. These have evaluated both short-term and long-term outcomes and have used German, Belgian,
and Spanish costings. A fifth prospective cohort study collected real outcomes and data on expenditure during a 1 year study follow-
up period. Results: All five studies have produced consistent results, showing the use of acamprosate, which enhances abstinence rates,
to reduce the total costs of treatment and thus be dominant over other rehabilitation strategies not involving pharmacotherapy. In all of
the studies, the principal cost-driver is hospitalization. Although there is a short-term increase in treatment costs associated with drug
acquisition, these are recovered from long-term savings attributable to reduced hospitalization and rehabilitation costs.
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Over the last decade, pharmacoeconomic studies have
become widespread in drug development programmes and in
health outcomes research. This has been driven by increasing
awareness on the part of health care decision makers on the
need to contain costs and, in consequence, by the need to
ensure that limited health care budgets can be apportioned in
such a way that the greatest therapeutic benefit is attained for
as many patients as possible. Many innovative treatments
represent a clear therapeutic advance over previous treatments,
but often at an increased financial cost. Therefore, it is
important to ensure that the extra expenditure required to
achieve an incremental unit of clinical efficacy is an efficient
use of resources compared with alternative interventions.
Alcohol dependence is a common condition associated
with high direct and indirect health care costs, principally
attributable to the management of secondary comorbidities
and lost productivity. Given the prevalence of alcohol-related
health problems, the total costs attributable to alcohol use
disorders represent a significant proportion of national health
care spending. In the US, untreated alcohol-users and drug-
users are among the highest cost users of health care (Zook
and Moore, 1980). Alcohol-dependent subjects have been
reported to consume up to 15 cents for every dollar spent on
health care in the US, mostly for the treatment of secondary
morbidity (Holder, 1987). A recent study from France has
suggested that costs owing to alcoholism correspond to ~1%
of the gross national product (Reynaud et al., 2001), while in
Finland, direct health costs alone represent ~0.6% of the gross
domestic product, while the total health costs may reach 4.3%
of the gross domestic product (Hein and Salomaa, 1999).
Thus, any treatment programme that interrupts the course of
chronic alcohol dependence or reduces its severity may result
in significant cost savings for society. Alcohol dependence
can be treated to some extent with psychosocial intervention
programmes or pharmacotherapy with abstinence-promoting
drugs or both. However, in spite of the large amount of
information available on the economic costs of alcohol
dependence, as well as extensive public awareness of this,
there is little data on the cost and savings associated with the
different detoxification and rehabilitation strategies used in
the management of alcohol dependence. In a 14 year survey of
health care spending by 3068 alcohol-dependent subjects
identified in a North American health insurance claims
database (Holder and Blose, 1991, 1992), total health care
expenditure rose with time in a more-or-less linear manner.
Costs rose steeply when the alcohol-related problem was
identified. From this moment, cost accrual was very different
according to whether the individual was successfully treated
or not. In untreated patients, costs continued to rise, whereas
in treated patients, costs fell to pre-diagnosis values over a 
3-year period. Expenditure for 23–55% of the patients fell to
below pre-treatment values.
Moreover, little data are available comparing the efficiency of
individual psychosocial and pharmacological interventions that
have been shown to be useful in treating alcohol dependence.
A study by Holder et al. (1991) compared the efficiency of
33 different treatment modalities using a semi-quantitative
categorical method. This identified large differences between
different treatments, with brief interventions being considered
the most cost-effective. This analysis was repeated and refined
5 years later (Finney and Monahan, 1996), and the ranking
system was somewhat changed. At this time, clinical trials of
pharmacological adjuvant therapy for alcohol dependence were
available. However, only oral and implanted disulfiram were
assessed with the former being considered not particularly cost-
effective. As part of Project MATCH, costs and savings were
determined in a prospective manner, and compared between
different psychosocial interventions (Holder et al., 2000).
Again, differences in the efficiency of the various treatment
options were observed in different patient populations, with
motivational enhancement therapy seeming to be the most cost-
effective overall.
Currently, the only pharmacological adjuvant therapy for
which cost-efficacy studies have been published is
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acamprosate. No such quantitative data are available on the
cost-efficacy of naltrexone or disulfiram. Acamprosate is an
abstinence-promoting drug that has been evaluated widely in
clinical trials (Mann, 2004) that have provided generally
consistent data on the relative treatment benefit in terms of
abstinence rates. A recent meta-analysis of these data has
estimated the relative risk of remaining abstinent conferred
by a 6 month treatment period with acamprosate in recently
detoxified subjects to be 1.47 (Mann et al., 2004). In addition,
there is evidence that acamprosate can reduce drinking in those
subjects who do not remain abstinent (Chick et al., 2003).
On the basis of these clinical data, and taking into account
the known health care costs associated with alcohol depen-
dence, a number of modelling studies have been performed in
order to estimate the efficiency associated with the use of
acamprosate in this population. In addition, a further cohort
study has measured health care costs and effectiveness
directly, comparing subjects taking acamprosate with those
without pharmacotherapy. The aim of this review is to provide
a critical assessment of these pharmacoeconomic studies in
the context of the overall costs of alcohol dependence.
PHARMACOECONOMIC STUDIES OF 
ACAMPROSATE
To date there have been five pharmacoeconomic analyses of
adjuvant acamprosate therapy (Table 1), all of which have
compared costs and outcomes between patients treated with
acamprosate and patients following an identical rehabilitation
regime without acamprosate.
The weaknesses of these studies are that all but one are
projections from diverse cost data sources, rather than direct
measures of expenditure obtained in actual clinical studies
with acamprosate. The majority of these have used Markov
models to predict costs and outcomes. The four modelling
studies were based on abstinence rates observed in published
randomized clinical trials of acamprosate, and known alcohol-
related costs. The fifth study was a prospective cohort study
performed in Germany, in which real costs were obtained. All
studies investigated direct medical costs and two evaluated
indirect costs as well. Certain modelling studies evaluated
short-term costs only, whereas others assessed long-term
projections including estimates of alcohol-related comorbidity
and mortality. The various cost variables assessed in the
different studies are presented in Table 2.
Markov modelling is a well-established method for
following changes in health states over time and assigning
economic parameters to outcomes (Briggs and Sculpher,
1998). These models are a form of decision tree analysis
where different nodes are arranged sequentially in time using
a stochastic approach, with a fixed interval of time between
the two nodes, such as 1 year. These nodes correspond to
different multinomial alternative outcomes (for example,
abstinence or relapse, hospitalization, occurrence of acute
hepatitis, etc.). To each of these nodes can be attributed a
probability value determining the event which is likely to
occur in a given time-period. These probabilities will differ
Table 1. Pharmacoeconomic studies performed with acamprosate
Reference Reference
Reference Direct/indirect country country Sensitivity
Study year Type Period costs —clinical —costs analysis
Schädlich and Brecht, 1998 1995 Markov Life Direct only Germany Germany Yes
model
Portella et al., 1998 1996 Markov 27 years Both Pooleda Spain Yes
model
Palmer et al., 2000 1996 Markov Life Direct only Germany Germany Yes
model
Annemans et al., 2000 1997 Markov 2 years Direct only Austria Belgium Yes
model
Rychlik et al., 2001 1997 Prospective 1 year Both Germany Germany NA
cohort study
NA, not applicable.
aThe clinical reference data for the Spanish cost-benefit study were pooled from a basket of published studies.
Table 2. Cost variables assessed in the different pharmacoeconomic studies performed with acamprosate
Schadlich Portella Palmer Annemans Rychlik
Study (Germany) (Spain) (Germany) (Belgium) (Germany)
Hospitalization     
Rehabilitation costs     
Drug acquisition costs     
Psychosocial support    
Laboratory tests  
GP visits   
3rd party health costs 
Lost productivity  
Travel costs 
Judicial costs 
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according to the hypothesis being tested (in this case treatment
with acamprosate vs no acamprosate) and are estimated either
from clinical trial data or natural history databases. At the end
of the decision tree are a finite number of health states (e.g.
abstinence, death, cirrhosis, and psychiatric disorder) to which
an economic cost can be attributed, which takes into account
the overall health care resources consumed by the patient
all along the trajectory. The distribution of subjects between
the finite health states will differ between the two treatments
evaluated in the base hypothesis as a function of the
probabilities assigned to each node, and thus the final cost is
different. Thus, a comparison can be made between the costs
and medical consequences accrued following the test
treatment and those accrued by a reference group. Hence, the
potential clinical benefit attributable to the treatment can be
calculated and balanced against the costs of treatment.
The validity of a given Markov model is evidently critically
dependent on the accuracy with which the probabilities
attributed to each node are known. For this reason, sensitivity
analysis is necessary to determine the extent to which the
results of the model are affected by varying these input
variables. The principal limitations of such modelling
techniques are the limited precision of the input probability
variables, the arbitrary choice of outcome parameters to
include in the model, which may not correspond to real cost
drivers in the real world, and the assumption that the different
probability values are independent of each other and do not
vary with time, which may be difficult to demonstrate.
Nevertheless, studies using Markov modelling techniques
allow the projection of short-term endpoints (such as
abstinence or controlled drinking) to long-term outcomes, such
as cirrhosis, hepatic carcinoma, and neurological disease. Such
information is often not feasible to obtain in a real prospective
study owing to limitations on the duration of the study.
FIRST GERMAN COST-EFFICACY ANALYSIS
The first modelling study to be published evaluated
differential costs associated with treatment using acamprosate
and placebo in the context of the German health care system
(Schädlich and Brecht, 1998). Both groups, active and placebo
received standard treatment. Abstinence rates were obtained
from a 1 year placebo-controlled clinical trial performed in
Germany including 272 subjects, with a 1 year non-treatment
follow-up period (Sass et al., 1996). The abstinence rates
were 39.9% for acamprosate-treated patients and 17.3%
for placebo-treated patients. The Markov model simply
postulated that the abstinent patients remained healthy (i.e. no
additional alcohol-related health care costs), whereas the
relapsing patients incurred costs related to further treatment of
alcohol dependence and the emergence of specific secondary
pathologies (alcohol-related psychosis and alcoholic liver
disease). The probabilities of these occurring were determined
from retrospective analysis of hospital records. The time-base
for the treatment period used in the pharmacoeconomic
modelling study exactly matched that used in the clinical
trial (2 years). The model predicted that treatment with
acamprosate for 1 year would avoid 34 cases of alcoholic
psychosis, 226 cases of continued alcohol dependence, 57
cases of acute alcoholic hepatitis, and 28 cases of alcoholic
liver cirrhosis for every 1000 subjects treated. The remaining
lifetime medical costs associated with these pathologies were
identified using standard German health care costs for
hospitalization (1993), rehabilitation treatment (1992), and
drug acquisition (1995), discounted at 5% per year. All costs
were subsequently adjusted for inflation to 1995 values in
DM. Costing was performed from the perspective of the
German health care system.
This study demonstrated lifetime savings attributable to
acamprosate treatment of €1300 (€1450 at 2004 values;
lower boundary: €226; upper boundary: €4921) per
additional abstinent patient (Fig. 1). These savings were
principally owing to reductions in hospitalization and
rehabilitation costs. A sensitivity analysis was performed in
which values for abstinence rates and duration of
hospitalization were varied. Acamprosate use was found to be
cost saving in 78% of the scenarios. The principal determinant
of efficiency was found to be the differential rate of
abstinence. The savings generated also varied according to
the unitary hospital costs. The study thus demonstrated that
acamprosate use led to a better clinical outcome at reduced
cost, and was thus dominant with respect to standard care in
terms of cost-efficacy.
A strength of this model is the high degree of confidence
with which probabilities could be assigned to the study
variables, because these were derived from data from a
randomized clinical trial. In addition, the time-frame for the
modelling cycle was identical to that used in the clinical trial,
allowing the relative abstinence rates of the two treatment
groups to be precisely attributed. The clinical source data and
the economic costings were obtained within the same time
period and the same health care system. Weaknesses of the
model are first, the assumption that all abstinent subjects will
generate no further alcohol-related health costs (i.e. there are
no long-term sequelae of previous drinking in patients who
achieve abstinence) may overestimate lifetime savings.
Second, the hypothesis that all relapsed subjects will generate
identical costs to untreated subjects is likely to be simplistic,
although consequences for the results of the model are likely
to be minimized by the use of mean costs in the estimates. The
most serious limitation is perhaps that the inclusion of only a
limited number of study variables in the model, while
increasing precision, may have led to the exclusion of
important cost drivers.
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Fig. 1. Cost breakdown for lifetime direct medical costs in patients
receiving standard care or standard care with adjuvant acamprosate
treatment. Data are taken from the modelling study by Schädlich and 
Brecht (1998).
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SECOND GERMAN COST-EFFICACY ANALYSIS
The same efficacy data were used in a second modelling study,
also from the German health service perspective (Palmer
et al., 2000). This predicted long-term clinical benefits and
consumption of health care resources accrued in a cohort of
males with an average age of 41 years. The principal
difference with the preceding study was in the complexity of
the Markov model. This started from the same premise of a
sustained relatively higher abstinence rate in acamprosate-
treated patients, and also assumed that relapsed patients would
continue to consume health care resources owing to further
treatment of alcohol dependence. However, it was assumed
that, at inclusion, excessive lifetime alcohol use would have
already led to alcohol-related disease in a significant
proportion of patients, resulting in future resource utilization
in patients who achieved abstinence. A large number of
alcohol-related pathologies were entered into the model, using
published epidemiological data to determine the probabilities.
These included liver pathologies, gastrointestinal disease,
alcoholic psychoses, cardiac myopathy, and peripheral
neuropathies. Moreover, the risk of suicide, accidental death,
or death resulting from one of the other pathologies were
introduced into the model. This enabled the impact of
treatment on mortality to be determined, and the cost per life-
year gained to be estimated.
This multi-parametric model predicted a lower incidence
of acute alcoholic psychosis, hepatic disease, gastrointestinal
pathologies, cardiomyopathy, suicide, and accidental death in
alcohol-dependent patients treated with acamprosate. This
would translate into decreased mortality, with life expectancy
in the standard care population being 14.7 years and in the
acamprosate cohort being 15.9 years. Discounted at 5% per
annum, this corresponded to a life-year gain of 0.52 years
attributable to acamprosate.
The lifetime direct medical costs in the acamprosate and
standard care groups were calculated using standard 1996
German health care costs for hospitalization, outpatient care,
and drug acquisition. In terms of costs, lifetime savings in
direct medical costs (discounted at 5% per annum) of €881
(€983 at 2004 values) per patient were predicted in the
acamprosate-treated population (Fig. 2). Confidence intervals
or other measures of precision were not provided. This figure
is rather lower than that put forward by Schädlich and Brecht
(see above); this difference could be attributed to the use of a
different algorithm and different assumptions in the Markov
model, notably the attribution of health costs to the patients
who remained abstinent. Nonetheless, this modelling study
also demonstrated that the use of acamprosate resulted in
significant net lifetime health care cost savings, in spite of the
acquisition costs of the drug itself.
Sensitivity analyses were conducted both for the treatment
effect on life expectancy and for the effect on cost. The
principal parameters that influenced the results on life
expectancy were the probabilities of developing cirrhosis, the
suicide rate, and the abstinence rate. Once again, the estimate
of abstinence rate was the most important determinant of costs
in this model. Nonetheless, even if the long-term abstinence
rate in acamprosate-treated patients was assumed to rejoin the
abstinence rate of untreated patients after 2 years (the longest
duration for which clinical trial data exist), acamprosate was
found to be cost-effective. Overall cost savings were indeed
predicted in all the scenarios evaluated in the sensitivity
analysis, as long as the drug acquisition costs did not rise
above €2230 per year (2004 values), which is far higher than
its current price.
The principal strength of this model lies in the extensive
range of health parameters modelled. In addition, the
likelihood that successfully treated subjects would continue
to accrue alcohol-related health care costs was taken into
account. Economic data and clinical data were obtained from
compatible sources. Once again, the weakness of the model is
that long-term predictions on costs and medical benefits are
made in the absence of any clinical data on the outcome
of acamprosate-treated subjects beyond 2 years of treatment.
However, the assumption of a sustained benefit is widely
accepted and the impact of this assumption was explicitly
addressed in the sensitivity analysis that showed acamprosate
treatment to be cost-saving even in the absence of a difference
in relapse rate beyond 2 years. Moreover, there is no evidence
for any rebound effect of acamprosate on drinking following
treatment discontinuation.
BELGIAN COST-BENEFIT ANALYSIS
A third study of the direct medical costs of alcohol
dependence from a health service perspective in patients
treated with acamprosate was performed in Belgium
(Annemans et al., 2000). This used data from an Austrian
placebo-controlled clinical trial of acamprosate (Whitworth
et al., 1996) to set the abstinence rates in the Markov model
for the two treatment groups. These absolute abstinence rates
are lower than in the German study, although the treatment
effect size is quite similar. Abstinence rates at each time-point
from this study were used for each of the monthly stages of the
Markov model. Twenty-four 1 month stages were modelled in
this study, with treatment with acamprosate being assumed
for the first year. The time-frame of the model thus exactly
matched that of the source clinical trial.
The Markov model principally evaluated outcomes related
to drinking relapse, and the health care costs associated with
treating this. These outcomes were outpatient follow-up,
institutional follow-up, outpatient detoxification, inpatient
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Fig. 2. Cost breakdown for lifetime direct medical costs in patients
receiving standard care or standard care with adjuvant acamprosate
treatment. Data are taken from the modelling study of Palmer et al. 
(2000), and represent non-discounted costs in 1996 Euro equivalents.
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detoxification, loss to follow-up, and death. Each of these
outcome states were allocated fixed physician consultation
costs, hospitalization costs (acute and long-term), drug costs,
and laboratory examination costs. These were based on
standard Belgian health care costs in 1997. The only
secondary alcoholic comorbidity included in the model was
liver disease (cirrhosis, but not liver cancer), as this was the
only one the evolution of which was expected to vary as a
function of abstinence outcome over the 2 year time-frame
of the study. A fixed cost for management of liver disease
(€11 977 per year; 2004 values) was allocated to 1% of
relapsing patients at each stage of the model, no cost being
allocated to abstinent patients.
The direct medical costs per patient over 2 years were
calculated to be €5255 (€5796 at 2004 values) for the
acamprosate treated cohort, and €5783 (€6379 at 2004 values)
for the standard care cohort. The cost savings attributable to
acamprosate use were thus €582 per patient over the 2 year
period. Once again, the principal cost reductions were those
imputable to hospitalization or rehabilitation (Fig. 3). No
precision estimates were provided. The authors calculated that
extrapolating this data to all alcohol-dependent patients
entering detoxification programmes in Belgium could result in
overall annual savings to the national health service of
€1.74–1.86 million (€1.92–2.05 million at 2004 values).
Sensitivity analyses were performed to evaluate the
influence of changes in the assumptions concerning the pro-
portion of patients followed-up for rehabilitation following
inpatient detoxification (acamprosate cost-saving at a follow-
up rate of 24%), the cost of short-term hospitalization
(acamprosate cost-saving at hospitalization costs of 50% of
actual costs), and the relapse rate in patients treated with
acamprosate (acamprosate cost-saving at a relapse rate of
59%). The latter was thus a critical determinant of cost-
efficiency. Again, precision measures for these sensitivity
analyses were not provided.
This model presents an advantage over the two previous
studies in that it only assessed health care costs over a 2 year
period, rather than lifetime. The probabilities assigned to the
nodes of the Markov model can thus be estimated with
confidence, and no assumptions are made about long-term
outcome for which no clinical data are available. On the other
hand, the cost data are derived from the Belgian health care
system, whereas the clinical data come from an Austrian
study in which abstinence rates were somewhat lower than
those observed elsewhere.
SPANISH COST-BENEFIT ANALYSIS
A large cost-benefit study performed in Spain (Portella et al.,
1998) has a very different scope and methodology from the
other modelling studies described above. The study assessed
costs attributable to alcohol dependence from both an
institutional and a societal perspective, and evaluated an
extensive array of direct cost items (hospitalization, physician
visits, rehabilitation, and drug acquisition) and indirect cost
items (lost working time and productivity, justice system and
police costs, and unrelated health expenses). The study used
national population reference data to identify an at-risk
population for alcohol dependence of 627 400 individuals in
Spain and rates of hospitalization for alcohol-attributable
illnesses (alcoholic psychosis, alcohol dependence, alcoholic
neuropathy, cardiomyopathy, gastritis, and liver disease) to
assign outcome probabilities. The time horizons of the study
were set by reference to the average age of initiation of
treatment for alcohol dependence (42 years), of hospital-
ization for liver disease (53 years), and of life expectancy in
Spain (69 years). Medium-term accrual of indirect costs up to
11 years and delayed accrual of costs attributable to emergent
secondary comorbidity from 11–27 years were estimated.
In the first step, the overall lifetime cost of treatment of all
alcohol-dependent patients in Spain was determined, using a
discount rate of 5% per annum. From this, an annual cost of
alcohol dependence of €1657 million (€1975 million at 2004
values) to the Spanish economy was calculated, correspond-
ing to €2640 per patient per year (€3147 at 2004 values).
Of the total costs, 25.7% corresponded to direct costs and
74.3% to indirect costs.
In the second step, the lifetime cost saving generated by the
successful rehabilitation of an individual patient with no
pathological sequelae was estimated to be €23 528 (€28 046
at 2004 values). In the final step, the net cost savings
attributable to acamprosate could be determined in each of
these scenarios, by incorporating in the model the drug acqui-
sition costs of acamprosate, and a differential abstinence rate
calculated from the basket of clinical trials of 29.1% for
acamprosate-treated patients and 22.0% for untreated patients.
The impact of treatment programmes could then be ascertained
in a variety of scenarios, relating to the prevalence of alcohol
dependence, the proportion of patients achieving stable
abstinence, and the proportion of rehabilitated patients free of
post-detoxification comorbidity. Net cost savings were
identified for acamprosate treatment regardless of the scenarios
envisaged. In the base-case scenario (50% of patients treated,
differential abstinence rate of 29.1%, and 50% of patients with
no long-term consequences) total potential cost savings were
estimated as €210 million (2004 values). These savings carried
from €39 million (2004 values) in the most conservative
scenario (40% of patients treated, differential abstinence rate of
10%, and 25% of patients with no long-term consequences) to
€261 million (2004 values) in the most optimistic scenario
(60% of patients treated, differential abstinence rate of 29.1%,
and 75% of patients with no long-term consequences).
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Fig. 3. Cost breakdown for 2 year direct medical costs in patients receiving
standard care or standard care with adjuvant acamprosate treatment. Data 
are taken from the modelling study of Annemans et al. (2000).
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Again the strength of this model lies in the range of
variables and outcomes assessed, and indeed this is the only
study to have estimated indirect costs and savings. The clinical
data were obtained from a basket of clinical trials performed
in different countries, which, on the one hand, more closely
approach ‘average’ treatment outcomes compared with single
studies in which observed abstinence rates may be dependent
on individual study protocols. On the other hand, the
assumptions that these pooled abstinence rates are applicable
to treatment programmes for alcohol dependence in Spain
cannot be tested. However, a subsequent clinical trial
performed in Spain (Gual and Lehert, 2001) provided an
estimate of the differential abstinence rate of 35%, somewhat
higher than that used in the modelling study. Indeed,
inspection of abstinence rates between studies performed in
different countries shows the treatment benefit attributable to
acamprosate to be quite similar from one study to the other
(Mann, 2004). The relative benefit in terms of continuous
abstinence associated with 6 months of treatment with
acamprosate estimated in the meta-analysis of 16 clinical trials
was 1.47. Another strength of the study lies in the modelling
of the outcome at two different time-horizons. However, the
projection of long-term outcome from the clinical trial data
remains problematic, as in the German study.
PROSPECTIVE GERMAN COST-EFFECTIVENESS
ANALYSIS
One study has attempted to measure actual costs attributable
to alcohol dependence in a real life study comparing standard
care alone with standard care using adjuvant acamprosate
(Rychlik et al., 2001). This German study followed 814
patients over a 1 year period, and documented all medical cost
outlay during this period, as well as indirect costs relating to
absenteeism and transport to consultations. The open-label
study was performed in a naturalistic setting that reflects
current standards of the management care of alcohol
dependence in Germany. This is an important design feature,
because it could be expected that abstinence rates may be
lower in such a setting than in the artificial environment of a
clinical trial where both physicians and patients are highly
motivated, and because sensitivity analyses in all the
modelling studies have shown that the abstinence rate is a
powerful determinant of the cost-efficiency of acamprosate.
In fact, the abstinence rates observed in the study (21.1% in
the standard care cohort and 33.6% in the acamprosate cohort)
were quite similar to those observed in the randomized clinical
trial of acamprosate performed in Germany (Sass et al., 1996).
This supports a recent report suggesting that abstinence rates
are similar in clinical trials and naturalistic settings (Pelc
et al., 2002), and that the abstinence rates chosen for the base
cases of the different modelling studies were appropriate.
Direct medical costs were significantly lower in the
acamprosate cohort than in the standard care cohort by €339
in 2004 (€363). These cost savings were generated mainly
by a reduced rate of hospitalization (Fig. 4). Indirect costs,
principally lost productivity, were also lower in the
acamprosate cohort, although this difference (€99; €106) was
not statistically significant. However, direct costs contributed
77% of the total costs measured. The cost-effectiveness of
standard care was evaluated at €9790 (€10 493 at 2004
values) per abstinent patient compared with a figure of €4857
(€ 5206 at 2004 values) per abstinent patient for acamprosate
treatment, a 2-fold difference. Precision estimates were not
provided.
This real-world study thus fulfilled the prediction of
previous modelling studies that adjuvant pharmacotherapy of
alcohol dependence with acamprosate could provide a better
clinical outcome at lower cost than could standard care.
Although it is difficult to compare the different studies
quantitatively, owing to methodological differences, this study
based on actual data is most similar to the Belgian modelling
study in that both assess short-term cost accrual (12 and 24
months time-frame). In fact, the two studies provide quite
similar estimates of cost-savings attributable to acamprosate
(the estimate of the real-life study being ~25% higher than that
of the Belgian modelling study). However, an important
difference between the studies is that acamprosate acquisition
costs are accrued over the entire 1 year study period of the
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Fig. 4. Cost breakdown for 1 year direct medical costs in patients receiving standard care or standard care with adjuvant acamprosate treatment. Data 
are taken from the prospective cohort study by Rychlik et al. (2001).
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German study, but only over the first half of the 2 year Belgian
study. Moreover, the modelling study restricted analysis to
costs associated with relapse and liver pathology, whereas the
real-life study measured all costs that actually occurred. Both
of these factors would be expected to lead to an underestimate
of the cost savings in the Belgian study, compared with real-
world conditions.
STRENGTHS AND WEAKNESSES
The information available on the cost-efficiency of
acamprosate has a number of strengths and weaknesses. The
principal strength relates to the robustness of the findings,
which is indicated by a number of observations. The results of
all the studies are coherent, providing a consistent finding that
the use of acamprosate provides better outcomes at lower cost
(Table 3). All these studies have shown acamprosate use to be
a dominant treatment strategy. Furthermore, the results of the
prospective cohort study performed in Germany have borne
out the predictions of the modelling studies.
The sensitivity analyses performed in all the modelling
studies have demonstrated that the cost-efficiency of
acamprosate is critically dependent on the abstinence rates
achieved with acamprosate. Since the Markov models used
data from only two clinical trials (Sass et al., 1996; Whitworth
et al., 1996), it is important to verify that the abstinence rates
demonstrated in these studies are representative, which can be
done easily by comparing data from all acamprosate published
clinical trials. Nonetheless, the abstinence rates obtained in
randomized clinical trials may not be representative of those
that can be achieved in the routine care of alcohol dependent
patients owing to the somewhat artificial conditions of the
clinical trials (restrictive inclusion criteria, aggressive follow-
up, motivated patients and investigators, etc.). This was first
assessed in a large open-label study conducted in five
European countries (Pelc et al., 2002), which demonstrated
that the abstinence rates obtained in naturalistic treatment
settings were similar to those reported in the randomized
clinical trials. Similarly, in the real-life pharmacoeconomic
study performed in Germany (Rychlik et al., 2001),
abstinence rates very similar to those in the German
randomized clinical trial were obtained (Sass et al., 1996)
(Table 4). Subsequently, a comparative naturalistic study
performed in France compared outcome after alcohol
detoxification using ‘standard care’ alone and using ‘standard
care’ with acamprosate (Kiritzé-Topor et al., 2004). The
treatment effect size in this study was commensurate with
that observed in the meta-analysis of the randomized placebo-
controlled clinical trials performed with acamprosate (Mann
et al., 2004). Therefore, it can be concluded that the
abstinence rates used in the pharmacoeconomic modelling
studies, are appropriate and representative of standard care.
The principal weakness of the information available is the
narrowness of the costing source database. Three of the five
studies have used German costings, and it is important to
extend these findings to countries where the health care cost
structure, or the price of acamprosate, are different. Moreover,
all the studies have demonstrated that hospitalization costs
are the principal determinant of the cost-efficiency of
acamprosate. Second, the long-term estimates should be
interpreted with caution, since we have no data on long-term
outcome from acamprosate beyond 2 years. However, one of
the German Markov models evaluated a scenario where the
treatment benefit with acamprosate on abstinence was lost
after 2 years, and concluded that acamprosate treatment was
still a cost-saving strategy in this case (Palmer et al., 2000).
In the Markov models, an assumption of no post-treatment
relapse has been made, but there is no direct evidence
available from long-term follow-up studies to support this.
Furthermore, little data is available on the impact of
acamprosate on indirect costs and savings. These are known
to be high, and American data have suggested that indirect
costs in family members could actually outstrip direct costs
in alcohol-dependent subjects themselves (Holder and Hallan,
1986). Finally, although sensitivity analyses address the issue
of robustness of the data, most of the studies provide no
explicit measure of the precision of the cost estimates. This
hinders comparison of the studies and notably precludes using
meta-analysis to attempt to compare cost savings across health
care systems.
Table 3. Cost savings per treated patient attributable to acamprosate use
Direct costs Indirect costs
Schädlich and Brecht, 1998
Germany €1450/life Not determined
Annemans et al., 2000
Belgium €291/year Not determined
Palmer et al., 2000
Germany €983/life Not determined
Portella et al., 1998
Spain Not provided Not provided
Rychlik et al., 2001
Germany €363/year €106/year
Costs are adjusted for inflation to 2004 values.
Table 4. Abstinence rates observed in clinical studies with acamprosate
Study Country Treatment period Placebo (%) Acamprosate (%) Ratio
Sass et al., 1996 Germany 1 year 17.3 39.9 2.31
Whitworth et al., 1996 Austria 1 year 7.4 18.3 2.47
Portella et al., 1998 10 EU 1 year 22.2 29.1 1.31
Rychlik et al., 2001 Germany 1 year 21.1a 33.6 1.59
Pelc et al., 2002 5 EU 6 months ND 24.4 ND
ND, not determined; EU, European Union.
a This was an open label-study where the group being compared received standard care only.
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DIRECTIONS FOR FUTURE RESEARCH
The pharmacoeconomic database for acamprosate could
usefully be extended to a number of new areas of research.
Most importantly, the source data for the clinical benefit of
acamprosate and for health care costs needs to be extended to
countries where the management of alcohol dependence is
different. At the moment, the clinical data used in the
modelling studies have come from two countries (Germany
and Austria) and the cost data from three (Germany, Belgium,
and Spain). The conclusions of the pharmacoeconomic
analysis for Germany can be considered robust, but it would
be useful to know whether they can be transposed to health
care systems where funding is assured by private insurance
rather than by national social security, such as in the US. In the
US, and many other countries, inpatient detoxification is less
widely used than in Germany; because hospitalization is a
major component of the cost savings attributed to
acamprosate, it would be important to verify that the cost-
efficiency of acamprosate is maintained in health care systems
where hospitalization for alcohol dependence is less frequent.
The currently available pharmacoeconomic data have been
obtained from studies built on the hypothesis that the effect
of acamprosate is to increase the probability of achieving
abstinence. However, in everyday practice, potential outcomes
encompass not only abstinence and relapse, but also a
reduction in drinking compared with pre-treatment levels.
Since the direct medical costs of alcohol dependence are
closely associated with the severity of dependence (McKenna
et al., 1996), such an outcome would be expected to result in
cost savings. Acamprosate has indeed been demonstrated to
reduce alcohol consumption in subjects included in the
acamprosate clinical trial programme (Chick et al., 2003).
This point is particularly important in order to evaluate
acamprosate treatment strategies where the drug is used
without a prior formal detoxification, such as was used in the
North American clinical trial of acamprosate (Mason, 2001).
The long-term economic impact of acamprosate treatment
has been modelled assuming that abstinence rates observed at
the end of the observation periods of clinical trials (2 years)
are sustained, and this assumption merits validation. Because
acamprosate has now been available in certain countries for
over 10 years, it should be possible to address this issue through
analysis of long-term outcome recorded in patient registries.
Little information is available on the impact of acamprosate
on the indirect costs of alcohol dependence. Since these
outweigh direct costs, this impact may be significant. A recent
observational study (Kiritzé-Topor et al., 2004) has
demonstrated that acamprosate reduces the social
consequences of alcohol dependence as measured with the
Alcohol-Related Problems Questionnaire (Chick et al., 1991;
Patience et al., 1997). This scale quantifies a number of non-
medical consequences of alcohol dependence, such as legal,
professional, or family problems. Such an approach may be
suitable for quantifying the impact of acamprosate on the
indirect costs of alcohol dependence.
It would also be useful to compare the cost-efficiency of
treatment using acamprosate with that of other pharmacological
adjuvant treatments used in the rehabilitation of alcohol-
dependent patients, such as naltrexone or disulfiram, for neither
of which any pharmacoeconomic data has been published.
The ongoing COMBINE study in the US (The COMBINE
Study Research Group, 2003) that compares treatment with
acamprosate, naltrexone, or both combined with different levels
of psychosocial intervention, may provide the necessary
outcome data to perform a comparative modelling study of the
cost-effectiveness of naltrexone and acamprosate.
Finally, the data on acamprosate could usefully be
completed with cost-utility studies in which adjustments are
made for changes in the quality of life. Since other studies
have indeed demonstrated that acamprosate treatment
improves the poor quality of life observed in alcohol-
dependent patients (Morgan et al., 2004), pharmacoeconomic
studies addressing cost-utility would be expected to reinforce
the economic argument for using acamprosate.
CONCLUSIONS
There is an extensive body of pharmacoeconomic data relating
to the use of acamprosate in the treatment of alcohol
dependence. This has included short-term and long-term
modelling studies, as well as one prospective real-life study.
All these studies have produced consistent results, showing the
use of acamprosate to improve clinical outcome and reduce the
total costs of treatment and thus be dominant over other
rehabilitation strategies not involving pharmacotherapy with
acamprosate. In consequence, treatment with acamprosate is
highly attractive from a health economics point of view. The
principal driver on the reduction of costs is reduced
hospitalization. Although there is a short-term increase in
treatment costs associated with drug acquisition, these are
recovered from long-term savings attributable to reduced
hospitalization and rehabilitation costs. Savings in direct
medical costs alone outweigh acquisition costs but cost savings
accrue both in direct and indirect costs. The funding of the
treatment of alcohol dependence by acamprosate is thus both
economically and clinically justified for health care payers.
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